The field then suffered a major setback when an Arizona teenager died in a gene therapy experiment in 1999 and two French boys with SCID developed leukemia in 2002.
The Glaxo gene therapy program will focus on a severe immune deficiency called ADA-SCID, in which kids cannot make a crucial enzyme called adenosine deaminase that is needed to create immune system cells.
Originally the trials were considered a huge success when a number of patients were successfully treated for the X-linked Severe Combined Immunodeficiency Syndrome (X-Scid) which is more commonly known as the "Boy in the Bubble" syndrome.
The idea of treating disease by replacing a defective gene with a working copy gained credence in 1990 with the success of the world's first gene therapy clinical tests against a rare condition called severe combined immunodeficiency (SCID).